
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Synteract has launched the Synteract Rare Disease Institute. The program incorporates lectures, webinars, interactive discussions, videos, and industry literature that cover a wide variety of topics from patient perspectives, bioethics to customer engagement and more.
For more information, click






